Virtu Financial LLC Invests $375,000 in Boston Scientific Co. (BSX)

Virtu Financial LLC bought a new stake in Boston Scientific Co. (NYSE:BSX) during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 10,434 shares of the medical equipment provider’s stock, valued at approximately $375,000.

Other institutional investors have also recently bought and sold shares of the company. Moody National Bank Trust Division acquired a new position in shares of Boston Scientific in the third quarter valued at approximately $108,000. Vantage Investment Advisors LLC grew its position in shares of Boston Scientific by 82.4% in the third quarter. Vantage Investment Advisors LLC now owns 2,989 shares of the medical equipment provider’s stock valued at $115,000 after purchasing an additional 1,350 shares during the last quarter. Stratos Wealth Partners LTD. acquired a new position in shares of Boston Scientific in the third quarter valued at approximately $119,000. Quad Cities Investment Group LLC acquired a new stake in Boston Scientific during the second quarter worth approximately $104,000. Finally, Captrust Financial Advisors grew its position in Boston Scientific by 103.8% during the second quarter. Captrust Financial Advisors now owns 3,129 shares of the medical equipment provider’s stock worth $102,000 after buying an additional 1,594 shares in the last quarter. 90.85% of the stock is currently owned by institutional investors.

In other news, EVP David A. Pierce sold 5,000 shares of the stock in a transaction on Monday, December 3rd. The stock was sold at an average price of $38.11, for a total value of $190,550.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Kevin J. Ballinger sold 37,430 shares of the stock in a transaction on Monday, September 24th. The shares were sold at an average price of $38.00, for a total value of $1,422,340.00. The disclosure for this sale can be found here. Insiders sold a total of 346,161 shares of company stock valued at $13,009,952 over the last quarter. 0.73% of the stock is owned by corporate insiders.

BSX has been the topic of a number of analyst reports. Raymond James increased their price target on Boston Scientific from $40.00 to $41.00 and gave the stock a “strong-buy” rating in a research report on Tuesday, September 4th. Barclays initiated coverage on Boston Scientific in a research report on Monday, October 15th. They set an “overweight” rating and a $43.00 price target on the stock. Guggenheim increased their price target on Boston Scientific to $45.00 and gave the stock a “buy” rating in a research report on Friday, November 16th. Oppenheimer reissued a “hold” rating on shares of Boston Scientific in a research report on Wednesday, November 21st. Finally, Jefferies Financial Group raised Boston Scientific from a “hold” rating to a “buy” rating and increased their price target for the stock from $34.00 to $42.00 in a research report on Tuesday, September 4th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating, twenty have given a buy rating and three have issued a strong buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average price target of $39.54.

NYSE BSX opened at $37.10 on Thursday. The company has a debt-to-equity ratio of 0.58, a current ratio of 0.78 and a quick ratio of 0.56. Boston Scientific Co. has a fifty-two week low of $24.79 and a fifty-two week high of $39.44. The firm has a market cap of $50.59 billion, a price-to-earnings ratio of 29.44, a price-to-earnings-growth ratio of 2.41 and a beta of 0.70.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings results on Wednesday, October 24th. The medical equipment provider reported $0.35 EPS for the quarter, beating the Zacks’ consensus estimate of $0.34 by $0.01. Boston Scientific had a return on equity of 26.44% and a net margin of 6.93%. The company had revenue of $2.39 billion during the quarter, compared to analysts’ expectations of $2.40 billion. During the same period in the prior year, the company earned $0.31 EPS. Boston Scientific’s revenue was up 7.7% compared to the same quarter last year. As a group, analysts predict that Boston Scientific Co. will post 1.39 EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This piece was originally posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this piece on another website, it was illegally copied and reposted in violation of US & international copyright laws. The legal version of this piece can be read at https://www.dispatchtribunal.com/2018/12/13/virtu-financial-llc-invests-375000-in-boston-scientific-co-bsx.html.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: Cardiovascular, Rhythm Management, and MedSurg. The company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions therapy products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as certain peripheral vessels; and structural heart therapy systems.

Featured Article: How interest rates affect municipal bond prices

Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Co. (NYSE:BSX).

Institutional Ownership by Quarter for Boston Scientific (NYSE:BSX)

Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply